iANTHUS CAPITAL HOLDINGS (ITHUF) Consolidated Net Income (2020 - 2026)
iANTHUS CAPITAL HOLDINGS's (ITHUF) quarterly Consolidated Net Income came in at -$14.3 million in Q1 2026, down 377.84% year-on-year from $5.1 million in Q1 2025, and down 1.55% quarter-over-quarter from -$14.1 million in Q4 2025.
iANTHUS CAPITAL HOLDINGS (ITHUF) Consolidated Net Income (2020 - 2026) Analysis & Trends
iANTHUS CAPITAL HOLDINGS has disclosed Consolidated Net Income across 7 years of filings, most recently posting -$14.3 million for Q1 2026.
- Consolidated Net Income for Q1 2026 came in at -$14.3 million, down 377.84% year-over-year; the trailing twelve-month figure through Mar 2026 was -$59.7 million (down 580.92% YoY), and the FY2025 annual result was -$40.2 million, down 44.05% from the prior year.
- Consolidated Net Income came in at -$14.3 million for Q1 2026 at iANTHUS CAPITAL HOLDINGS, down from -$14.1 million in the prior quarter.
- In the past five years, Consolidated Net Income ranged from a high of $7.5 million in Q4 2024 to a low of -$373.6 million in Q2 2022.
- The 5-year median for Consolidated Net Income is -$14.3 million (2026), against an average of -$35.8 million.
- Across the five-year window, Consolidated Net Income sank 2348.62% in 2022 and jumped 140.22% in 2024, its largest moves.
- iANTHUS CAPITAL HOLDINGS's Consolidated Net Income stood at -$43.7 million in 2022, then surged by 57.25% to -$18.7 million in 2023, then jumped by 140.22% to $7.5 million in 2024, then slumped by 287.39% to -$14.1 million in 2025, then retreated by 1.55% to -$14.3 million in 2026.
- The last three Consolidated Net Income figures came in at -$14.3 million (Q1 2026), -$14.1 million (Q4 2025), and -$12.5 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Consol Net Inc. (Qtr) |
|---|---|---|---|---|---|
| 1 | Teva Pharmaceutical Industries | 38.34 Bn | 34.60 Bn | 1.97 Bn | 370.00 Mn |
| 2 | Zoetis | 33.27 Bn | 31.33 Bn | 1.62 Bn | 601.00 Mn |
| 3 | United Therapeutics | 23.75 Bn | 21.60 Bn | 648.10 Mn | 274.90 Mn |
| 4 | Aurora Cannabis | 17.11 Bn | 17.03 Bn | 33.43 Mn | -114,733.81 |
| 5 | Neurocrine Biosciences | 16.37 Bn | 15.05 Bn | 800.70 Mn | 197.90 Mn |
| 6 | Elanco Animal Health | 11.78 Bn | 11.35 Bn | 785.00 Mn | 57.00 Mn |
| 7 | Alkermes | 7.05 Bn | 6.54 Bn | -116.06 Mn | -66.53 Mn |
| 8 | Lantheus Holdings | 6.49 Bn | 5.99 Bn | 230.92 Mn | 118.42 Mn |
| 9 | Hims & Hers Health | 6.19 Bn | 5.44 Bn | 396.79 Mn | -92.12 Mn |
| 10 | iANTHUS CAPITAL HOLDINGS | - | - | 15.92 Mn | -14.31 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -14.31 Mn |
| Dec 31, 2025 | -14.09 Mn |
| Sep 30, 2025 | -12.55 Mn |
| Jun 30, 2025 | -18.72 Mn |
| Mar 31, 2025 | 5.15 Mn |
| Dec 31, 2024 | 7.52 Mn |
| Sep 30, 2024 | -11.64 Mn |
| Jun 30, 2024 | -9.79 Mn |
| Mar 31, 2024 | -14.00 Mn |
| Dec 31, 2023 | -18.70 Mn |
| Sep 30, 2023 | -19.18 Mn |
| Jun 30, 2023 | -20.15 Mn |
| Mar 31, 2023 | -18.60 Mn |
| Dec 31, 2022 | -43.73 Mn |
| Sep 30, 2022 | -22.00 Mn |
| Jun 30, 2022 | -373.56 Mn |
| Mar 31, 2022 | -10.10 Mn |
| Dec 31, 2021 | -26.95 Mn |
| Sep 30, 2021 | -15.84 Mn |
| Jun 30, 2021 | -15.26 Mn |